Novartis posts 82% remission rate in CAR T paediatric study
December 5, 2016Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric
Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …
Pfizer teams up with IBM Watson Health in immuno-oncology
December 2, 2016Medical Communications Pfizer, Watson, Watson Health, drug discovery, ibm
Pfizer and IBM Watson Health have announced a joint venture to accelerate research in immuno-oncology. Pfizer will use IBM’s Watson …
Top Ten most popular articles on Pharmafile this week
December 2, 2016Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories
This week has been an interesting one for pharmaceutical innovation. A number of stories and studies have arisen about trialling …
Looking back at the biggest deal of 2016: Bayer-Monsanto
December 2, 2016Medical Communications Bayer, acquisition, big deal, monsanto, pharma deal 2016
The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September …
J&J hit by $1bn hip implant lawsuit
December 2, 2016Medical Communications J&J, JJ, lawsuit
Johnson & Johnson have been hit with yet another payout to patients who claim its products caused them harm. First, …
AstraZeneca seals $1 billion deal with Bicycle Therapeutics
December 2, 2016Medical Communications, Sales and Marketing AstraZeneca, Bicycle Therapeutics
Bicycle Therapeutics, Cambridge-based British biotech firm, has announced that it has signed a deal that could potentially be worth over …
NICE approves MSD’s Keytruda for new cancer indication
December 1, 2016Medical Communications, Sales and Marketing MSD, NICE, keytruda
The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …
Kite Pharma names new senior VP of Supply Chain
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, kite pharma
Santa-Monica-based clinical-stage biopharmaceutical firm Kite Pharma has appointed Dr Jian Irish as senior vice president of Supply Chain, who will …
Takeda to build €100 million dengue vaccine manufacturing plant
December 1, 2016Manufacturing and Production, Medical Communications Takeda, dengue, phase 3
Takeda have announced plans to spend more than €100 million in the construction of a new manufacturing plant in Singen, …
Eisai & Clinigen to bring breast cancer drug to South Africa
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, Eisai, South Africa, breast cancer
Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa …
Cancer Research UK announces “largest ever” development investment
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer Research UK
Cancer Research UK (CRUK) is set to inject a total of £226 million into centres across the UK over the …
Illegal psilocybin shows promise in treatment of depression
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Johns Hopkins, Magic mushrooms, psilocybin
A double-blind study of psilocybin, the hallucinogenic drug chemical found in ‘magic mushrooms’, has been found to have substantial mental …
NICE recommends GSK’s “first-in-class” asthma drug
November 30, 2016Sales and Marketing GSK, NICE, Nucala, asthma
NICE has announced its recommendation of GSK’s “first-in-class” biologic Nucala (mepolizumab) as an extra option for the treatment of adults …
Researchers develop capsule-based haemophilia treatment tech
November 30, 2016Research and Development University of Texas, haemophilia
Researchers at the University of Texas have developed a new method for treating haemophilia B which utilises a biodegradable oral …
Teva to shut down Maltese plant, axe 210 jobs
November 30, 2016Manufacturing and Production, Research and Development Actavis Generics, Allergan, Malta, Teva
Teva is set to axe 210 jobs and shut down a production plant in Malta in an effort to cut …
£25m flagship manufacturing & research facility for University of Nottingham
November 30, 2016Manufacturing and Production, Research and Development University of Nottingham
Earlier this month, the University of Nottingham began work on a ‘pioneering’ Advanced Manufacturing Building. The £25 million, 9,011 square-metre …
Humira biosimilar proves efficacy in Phase 3 trial
November 30, 2016Research and Development AbbVie, Amgen, FDA, Humira, M923, Momenta
US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …
MDMA trials get FDA backing for PTSD treatment
November 30, 2016Research and Development FDA, MDMA, PTSD
The FDA have given the go-ahead to Phase 3 clinical trials investigating the efficacy of MDMA (Methylenedioxymethamphetamine) for treating post-traumatic …
Actinium snatches up ex-Novartis clinical manager
November 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actinium, Novartis, appointment
Actinium Pharmaceuticals has appointed Gregory Bergonio to the position of director of Clinical Operations, where he will first guide the …
NICE recommends 4p breast cancer drug for healthy women
November 29, 2016Research and Development, Sales and Marketing NICE, anastrozole, breast cancer
NICE has published new draft guidance calling for women with a strong family history of breast cancer to be offered …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
